UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer

Cancer research (Chicago, Ill.), 2018-01, Vol.78 (1), p.246-255

2018

Volltextzugriff (PDF)

601 Development of improved small molecule STING agonists suitable for systemic administration

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A636-A636

2020

Volltextzugriff (PDF)

Abstract 1281: Development and characterization of small molecule HPK1 inhibitors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1281-1281

2021

Volltextzugriff (PDF)

Abstract 3656: Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.3656-3656

2020

Volltextzugriff (PDF)

Abstract 4532A: Development of selective small molecule STING agonists suitable for systemic administration

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4532-4532A

2020

Volltextzugriff (PDF)

AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.973-999

2020

Volltextzugriff (PDF)

Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5690-5690

2020

Volltextzugriff (PDF)

Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3774-3774

2018

Volltextzugriff (PDF)

A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21043-e21043

2018

Volltextzugriff (PDF)

Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.626-626

2017

Volltextzugriff (PDF)

Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324

Blood, 2015-12, Vol.126 (23), p.4931-4931

2015

Volltextzugriff (PDF)

Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.566-566

2016

Volltextzugriff (PDF)

AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer

iScience, 2020-11, Vol.23 (11), p.101649-101649, Article 101649

2020

Volltextzugriff (PDF)

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.1747-1747

2014

Volltextzugriff (PDF)

Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models

Clinical cancer research, 2014-01, Vol.20 (2_Supplement), p.B30-B30

2014

Volltextzugriff (PDF)

Abstract PO-49: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B-cell lymphomas

Blood cancer discovery, 2020-11, Vol.1 (3_Supplement), p.PO-49-PO-49

2020

Volltextzugriff (PDF)

Abstract 4888: Axl receptor signaling in required for stem cell traits and metastasis in breast cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4888-4888

2013

Volltextzugriff (PDF)

Abstract C76: Axl signaling is required for stem cell traits and metastasis in breast cancer

Cancer research (Chicago, Ill.), 2013-02, Vol.73 (3_Supplement), p.C76-C76

2013

Volltextzugriff (PDF)

Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.B014-B014

2016

Volltextzugriff (PDF)

Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.B027-B027

2016

Volltextzugriff (PDF)

Drivers of EMT and Immune Evasion

Biomarkers of the Tumor Microenvironment, p.183-194

Volltextzugriff (PDF)

Drivers of EMT and Immune Evasion

Biomarkers of the Tumor Microenvironment, p.221-239

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(22)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Kollektion

4 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer

601 Development of improved small molecule STING agonists suitable for systemic administration

Abstract 1280: New generation of STING agonists: Development and characterization of a novel series of systemic immunomodulators with improved potency

Abstract 1281: Development and characterization of small molecule HPK1 inhibitors

Abstract 3656: Development of novel, selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1) mutated tumors

Abstract 4532A: Development of selective small molecule STING agonists suitable for systemic administration

Abstract 1947: Development and characterization of small molecule HPK1 inhibitors

AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells

Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas

Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy

A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC

Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models

Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324

Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models

Abstract PO-49: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B-cell lymphomas

Abstract 4888: Axl receptor signaling in required for stem cell traits and metastasis in breast cancer

Abstract C76: Axl signaling is required for stem cell traits and metastasis in breast cancer

Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy

Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy

Drivers of EMT and Immune Evasion

Drivers of EMT and Immune Evasion

Suchergebnisse filtern